Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2020 · 10-Q
Revenue$5.45M$5.45M−13.1% vs Q2 2019 Net Income-$5.58M-$5.58MN/M vs Q2 2019 EPS Diluted-$1.38-$1.38N/M vs Q2 2019 Gross Profit$1,596,000−50.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$449,000N/M Margins · derivedGross margin29.3%−22.4 pt vs Q2 2019
Operating margin-106.0%−20.7 pt vs Q2 2019
Net margin-102.5%−17.9 pt vs Q2 2019
ended Jun 30, 2020 · filed Oct 19, 2020 · 111 d after period end